A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs ALX 148 (Primary) ; Atezolizumab (Primary) ; Trastuzumab (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Alexo Therapeutics
- 05 Oct 2017 According to an Alexo Therapeutics media release, data will be presented at the SITC 32nd Annual Meeting 2017.
- 10 Apr 2017 According to an Alexo Therapeutics media release, company has initiated dosing in this trial.
- 09 Feb 2017 Status changed from not yet recruiting to recruiting.